Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BNT162b1 in Healthy Chinese Subjects
NCT04523571Phase 1Completed
- Sponsor
- BioNTech SE
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BNT162b1 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by BioNTech SE. Primary endpoints: Number of Participants With Solicited Local Adverse Events, Number of Participants With Solicited Systemic Adverse Events and 1 more. Started Jul 2020; status: completed.
02
Drugs
BNT162b1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04523571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523571.